Shilpa Medicare's subsidiary, Shilpa Biologicals, has signed a co-development and supply agreement with Finland's Orion Corporation for a Nivolumab biosimilar in Europe. This leverages Shilpa's manufacturing in India for the European market.

Shilpa Medicare and Orion Corporation Forge European Biosimilar Partnership

Shilpa Medicare Ltd, via its subsidiary Shilpa Biologicals Private Limited, has entered a co-development and supply agreement with Finland-based Orion Corporation, extending their existing collaboration.

Reader Takeaway: Shilpa leverages its Indian manufacturing for European biosimilar sales; Orion handles European marketing.

What just happened

Shilpa Biologicals will develop, manufacture, and exclusively supply a Nivolumab biosimilar for the European market. Orion Corporation will be responsible for obtaining marketing authorization, registration, and handling sales and distribution across Europe.

Why this matters

This partnership targets the significant European Nivolumab biosimilar market, estimated to reach USD 4.1 billion by 2025. It allows Shilpa to capitalize on the loss of exclusivity for the originator drug by providing an EU-GMP manufactured alternative.

The agreement combines Shilpa's expertise in biologics development and manufacturing with Orion's established European commercial network, creating a strategic synergy.

The backstory

This deal builds on a previous collaboration between Shilpa and Orion concerning Recombinant Human Albumin, indicating a positive and trusted working relationship.

What changes now

Shilpa Biologicals will utilize its EU-GMP certified facility in Dharwad, India, as the exclusive long-term manufacturing site. Orion will manage the regulatory and commercial aspects in Europe.

Financial Implications

Shilpa Biologicals is set to receive development and regulatory milestone payments, followed by recurring supply revenue over the partnership's duration. Specific financial details remain confidential.

Context: Orion Corporation

Orion Corporation is a Nordic pharmaceutical company focused on oncology and pain management, reporting EUR 1,890 million in net sales in 2025 with about 4,000 employees.

Risks to watch

Regulatory approvals in Europe and successful market penetration against potential competitors will be key. The financial upside is dependent on milestone achievement and commercial success.